GlobeNewswire (Thu, 4:30PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
495 people get MNTA articles and Market Currents by email alert.
Get email alerts on MNTA »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 15, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
GlobeNewswire (Nov 27, 2012)
-
GlobeNewswire (Nov 20, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
Momenta's Lovenox Win Should Value It HigherGuruFundPicks • Mon, Oct 31, 2011 -
Momenta Pharma: On a Roll in 2011Kinetic Investments • Thu, May 12, 2011 -
-
-
-
-
Momenta Pharma: A Waiting GameMike Havrilla • Fri, Sep 26, 2008
-
Momenta Pharma: Expect Upside Following Game-Changing UpgradeNotable Calls • Mon, Apr 28, 2008 -
Is Momenta's Stock Plunge Justified?Anthony Payne • Mon, Feb 12, 2007
-
-
4 Low-Debt Healthcare Stocks Raking In ProfitsZetaKap • Fri, Sep 14, 2012 -
-
7 Profitable Healthcare Stocks That Analysts LoveZetaKap • Fri, Aug 10, 2012
-
-
-
-
5 Analyst-Backed Healthcare Stocks Raking In ProfitsZetaKap • Tue, Jul 3, 2012
-
-
-
-
-
-
Biotechnology And Drugs Stocks To Watch For Next WeekStockPandit • Wed, Apr 25, 2012
-
-
-
-
-
-
-
Momentas' CEO Discusses Q2 2012 Results - Earnings Call TranscriptThu, Aug 2, 2012
-
GlobeNewswire (Thu, 4:30PM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (Apr 30, 2013)
-
GlobeNewswire (Apr 9, 2013)
-
GlobeNewswire (Feb 25, 2013)
-
GlobeNewswire (Feb 15, 2013)
-
GlobeNewswire (Feb 7, 2013)
-
at CNBC.com (Jan 9, 2013)
-
GlobeNewswire (Nov 27, 2012)
-
GlobeNewswire (Nov 20, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Oct 18, 2012)
-
GlobeNewswire (Aug 30, 2012)
-
GlobeNewswire (Aug 8, 2012)
-
GlobeNewswire (Aug 2, 2012)
-
GlobeNewswire (Jul 16, 2012)
-
GlobeNewswire (Jul 2, 2012)
MNTA vs. ETF Alternatives
Company Description
Momenta is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, like heparan-sulfate proteoglycans, or HSPGs. This results in a diversified product... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, April 30, 3:43 PM Momenta Pharmaceuticals (MNTA -3.7%) slides after reporting a wider than expected Q1 loss this morning. The company attributes the miss to the January 2012 launch of a competitor's generic Lovenox, causing decreased unit sales and lower market share, which in turn led to lower prices in response to competitor pricing reductions. Comment! [Healthcare, On the Move, Earnings]
- Tuesday, April 30, 8:06 AM Momenta Pharmaceuticals (MNTA): Q1 EPS of -$0.48 misses by $0.03. Revenue of $7.6M misses by $2.68M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, April 30, 12:05 AM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS Comment! [Earnings]
- Monday, April 29, 5:30 PM Notable earnings before Tuesday’s open: ABFS, AET, AGCO, AMED, ARCO, AVP, BEN, BP, CIE, CMI, CNH, COCO, CRIS, CYNO, DBD, DDD, DPZ, ECL, EPD, ESV, EXAS, FCH, FIS, FLWS, GAS, GOV, HCLP, HCP, HEP, HNR, HOT, HRS, HUN, HW, IVZ, KLIC, LM, MCGC, MHP, MLM, MNTA, MPC, MPLX, MSO, MTG, MTOR, MWV, NEE, NI, NYX, ODP, OSK, PBI, PEG, PES, PFE, ROC, SAVE, SIRI, TFX, THC, TRI, TRW, UBS, UDR, VLO, VSH, WEC, X, XYL, ZTS 1 Comment [Earnings]
- Friday, February 15, 10:35 AM Momenta Pharmaceuticals (MNTA +0.6%) gains on a solid Q4 earnings beat, but losses continue to widen and total revenue declined by 57% Y/Y. Total collaboration revenue was $12.7M, down from $29.5M a year prior due to declining enoxaparin sales. The company reafirms guidance going forward, noting that it expects total operating expenses to average $30M per quarter for 2013. Comment! [Healthcare, Earnings]
- Friday, February 15, 8:06 AM Momenta Pharma (MNTA): Q4 EPS of -$0.35 beats by $0.07. Revenue of $12.73M beats by $2.32M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, February 15, 12:05 AM Notable earnings before Friday’s open: AEP, BAM, BKW, CPB, DLR, ENB, IPGP, KRFT, MNTA, RCI, SFL, SJM, SNH, TRW, UPL, VFC, VTG, VTR Comment! [Earnings]
- Thursday, February 14, 5:30 PM Notable earnings before Friday’s open: AEP, BAM, BKW, CPB, DLR, ENB, IPGP, KRFT, MNTA, RCI, SFL, SJM, SNH, TRW, UPL, VFC, VTG, VTR Comment! [Earnings]
-
Monday, November 19, 2012, 5:38 PM
After-hours top gainers, as of 5:15 p.m.: KKD +10.8%. LTRE +7.1%. GLUU +4.3%. QIHU +4.2%. RYL +3.4%.
After-hours top losers: MNTA -7.7%. MMLP -4.7%. JACK -4.7%. OVTI -4.1%. DELL -3.6%. Comment! [On the Move] - Wednesday, November 7, 2012, 8:13 AM Momenta Pharmaceuticals (MNTA): Q3 EPS of -$0.51 misses by $0.24. Revenue of $5.1M (-94.2% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Wednesday, November 7, 2012, 12:05 AM Notable earnings before Wednesday’s open: AES, AGU, ARIA, BDX, CLH, CNP, CTSH, CWH, DVN, ENB, FNP, GOLD, HFC, HSP, JRCC, LAMR, LEAP, M, MNTA, MPEL, NIHD, PRGO, SODA, SONS, STWD, TAP, THC, TICC, TWX, VICL, WFR, WLP, WRES Comment! [Earnings]
- Tuesday, November 6, 2012, 5:30 PM Notable earnings before Wednesday’s open: AES, AGU, ARIA, BDX, CLH, CNP, CTSH, CWH, DVN, ENB, FNP, GOLD, HFC, HSP, JRCC, LAMR, LEAP, M, MNTA, MPEL, NIHD, PRGO, SODA, SONS, STWD, TAP, THC, TICC, TWX, VICL, WFR, WLP, WRES Comment! [Earnings]
- Wednesday, August 15, 2012, 1:48 PM Questcor (QCOR +2%) trades up today after being mentioned positively at BofA/Merrill. The firm says that after taking a meeting with Momenta (MNTA), it's convinced a generic version of QCOR's Acthar is unlikely near-term. Concerns over competition for Acthar have been a deep overhang on the stock. Comment! [Healthcare, On the Move]
- Friday, August 3, 2012, 5:19 PM Momenta Pharmaceuticals (MNTA) says the U.S. Court of Appeals has issued its opinion supporting its previous decision to stay the preliminary injunction in the case against Amphastar Pharmaceuticals, Watson Pharmaceuticals (WPI) and International Medical Systems. MNTA CEO Craig Wheeler notes the opinion is a setback for the company and has "potentially wide ranging implications for all patent holders." Shares +3.6% AH. Comment! [Healthcare]
- Thursday, August 2, 2012, 10:38 AM Momenta Pharma (MNTA): Q2 EPS of -$0.2 misses by $0.03. Revenue of $21.9M (-75% Y/Y) beats by $2.91M. (PR) Comment! [Earnings, Healthcare]
- Friday, July 20, 2012, 12:25 PM Momenta Pharmaceutical (MNTA -5.7%) takes a hit after UBS downgraded the shares to Neutral earlier this morning, citing limited near-term catalysts and cash burn following the recent negative court ruling in the Copaxone case. The firm retains its price target of $15. Comment! [Healthcare, On the Move]